NIKKEI 225
29,683.09 +84.43 (+0.29%) HANG SENG
25,319.72 -330.36 (-1.29%) GOLD FUTURES
1,861.20 -0.20 (-0.01%) DOW
35,870.95 -60.10 (-0.17%) BTC-GBP
43,364.98 -513.73 (-1.17%) CMC Crypto 200
1,402.14 -65.80 (-4.48%)
Genfit SA (GNFT)
| Previous close | 3.4100 |
| Open | 3.4200 |
| Bid | 3.3500 x 800 |
| Ask | 3.8700 x 3200 |
| Day's range | 3.3500 - 3.4300 |
| 52-week range | 3.2600 - 7.1900 |
| Volume | |
| Avg. volume | 7,025 |
| Market cap | 153.701M |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.1090 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
Lille, France; Cambridge, MA; November 18, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique
- Globe Newswire
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
Lille, France; Cambridge, MA; November 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program. The open-label, non-randomized, 2-center, repeated-dose, parallel-group study will provide preliminary insight into NTZ pharmacokinetics (PK) and safe
- Globe Newswire
GENFIT: Third Quarter 2021 Financial Information
Cash and cash equivalents: €91.5 million as of September 30, 2021 Lille, France; Cambridge, MA; November 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2021 and revenues for the first nine months of 20211. Cash Position As of September 30, 2021, the Company’s cash and cash equivalents amounted to €91.5 million compared
